组织因子途径抑制剂内吞作用。

Tissue factor pathway inhibitor endocytosis.

机构信息

Departments of Pediatrics and Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

出版信息

Trends Cardiovasc Med. 1997 Oct;7(7):234-9. doi: 10.1016/S1050-1738(97)00083-2.

Abstract

Tissue factor pathway inhibitor (TFPI), a 42 kD protein, provides the physiological inhibition of tissue factor initiated coagulation by inhibition of both factor Xa and factor VIIa/tissue factor. In plasma, most TFPI is lipoprotein bound with an additional "releasable" pool bound to the endothelial cell surface. TFPI clearance is via receptor mediated endocytosis into liver. Heparin sulfate proteoglycans and LRP (low density lipoprotein receptor-related protein), an extremely large (∼600 kD) cell surface protein, primarily mediate this clearance, although additional TFPI binding sites and endocytosis pathways exist. (Trends Cardiovasc Med 1997; 7:234-239). © 1997, Elsevier Science Inc.

摘要

组织因子途径抑制剂（TFPI），一种 42kD 蛋白，通过抑制因子 Xa 和因子 VIIa/组织因子，提供了对组织因子引发的凝血的生理抑制作用。在血浆中，大多数 TFPI 与脂蛋白结合，还有一个“可释放”池与内皮细胞表面结合。TFPI 通过受体介导的内吞作用被清除到肝脏中。肝素硫酸蛋白聚糖和 LRP（低密度脂蛋白受体相关蛋白），一种非常大的（约 600kD）细胞表面蛋白，主要介导这种清除作用，尽管还存在其他 TFPI 结合位点和内吞途径。（趋势心血管医学 1997；7:234-239）。 © 1997 年，Elsevier Science Inc.